Robin Alexander, Owen Carolyn, Perry Sarah, Street Lesley, Chua Neil, Stewart Douglas, Puckrin Robert
Alberta Health Services and University of Calgary, Calgary, Canada.
Alberta Health Services and University of Alberta, Edmonton, Canada.
Eur J Haematol. 2025 Sep;115(3):260-265. doi: 10.1111/ejh.14443. Epub 2025 Jun 1.
Bendamustine-rituximab (BR) has demonstrated efficacy and tolerability in the treatment of various indolent B-cell lymphomas, but there is limited data regarding its outcomes in nodular lymphocyte predominant B-cell (Hodgkin) lymphoma (NLPBL).
This retrospective, population-based study included consecutive patients ≥ 18 years old who received BR for NLPBL in Alberta, Canada.
The study population comprised 23 patients with a median age of 39 years (range 18-74) who received BR for treatment-naive (n = 17) or relapsed/refractory (n = 6) NLPBL. Advanced stage disease was present in 18 (78%), splenic involvement in 9 (39%), and bone marrow involvement in 8 (35%) patients. The response rate to BR was 100%, with a complete response in 78% and a partial response in 22%. After a median follow-up of 4.3 years (range 0.8-9.0), the 4-year progression-free survival and overall survival rates were 83% (95% CI: 55%-94%) and 87% (95% CI: 58%-97%) for all patients and 84% (95% CI: 50%-96%) and 91% (95% CI: 51%-99%) for recipients of first-line BR, respectively. The safety profile was in keeping with the known toxicities of BR, with the most common adverse events consisting of neutropenia, rash, and infusion reactions.
These findings suggest that BR is a promising treatment option for NLPBL, with a favorable efficacy and safety profile.
苯达莫司汀-利妥昔单抗（BR）已在多种惰性B细胞淋巴瘤的治疗中显示出疗效和耐受性，但关于其在结节性淋巴细胞为主型B细胞（霍奇金）淋巴瘤（NLPBL）中的治疗结果的数据有限。
这项基于人群的回顾性研究纳入了加拿大艾伯塔省连续接受BR治疗NLPBL的≥18岁患者。
研究人群包括23例患者，中位年龄39岁（范围18 - 74岁），接受BR治疗初治（n = 17）或复发/难治性（n = 6）NLPBL。18例（78%）患者为晚期疾病，9例（39%）有脾受累，8例（35%）有骨髓受累。BR的缓解率为100%，完全缓解率为78%，部分缓解率为22%。中位随访4.3年（范围0.8 - 9.0）后，所有患者的4年无进展生存率和总生存率分别为83%（95%CI：55% - 94%）和87%（95%CI：58% - 97%），一线BR治疗患者分别为84%（95%CI：50% - 96%）和91%（95%CI：51% - 99%）。安全性与BR已知的毒性相符，最常见的不良事件包括中性粒细胞减少、皮疹和输注反应。
这些发现表明，BR是NLPBL一种有前景的治疗选择，具有良好的疗效和安全性。
